A new cost effectiveness analysis of Lp(a) testing for primary prevention, carried out for the FH Europe Foundation as part of the Lp(a) International Taskforce initiative, has demonstrated the potential for major cost savings across 11 high income countries*, together with reductions in cardiovascular events.
